| 2.32 -0.18 (-7.2%) | 12-12 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.07 | 1-year : | 3.58 |
| Resists | First : | 2.63 | Second : | 3.07 |
| Pivot price | 2.34  |
|||
| Supports | First : | 2.22 | Second : | 1.97 |
| MAs | MA(5) : | 2.47 |
MA(20) : | 2.28 |
| MA(100) : | 2.03 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 75.6 |
D(3) : | 84 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 3.81 | Low : | 1.38 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ WHWK ] has closed above bottom band by 45.5%. Bollinger Bands are 51.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.54 - 2.56 | 2.56 - 2.57 |
| Low: | 2.29 - 2.3 | 2.3 - 2.32 |
| Close: | 2.3 - 2.32 | 2.32 - 2.34 |
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
Mon, 01 Dec 2025
Whitehawk therapeutics names Margaret Dugan as chief medical officer - Investing.com
Mon, 01 Dec 2025
Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer - PR Newswire
Thu, 20 Nov 2025
Whitehawk Therapeutics stock holds steady as Jefferies maintains rating - Investing.com
Thu, 06 Nov 2025
Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights - PR Newswire
Sat, 01 Nov 2025
Hedge funds investors own a significant stake of 37% in Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) - Yahoo Finance
Fri, 17 Oct 2025
Whitehawk Therapeutics Dips Over 8% In After-Hours Trading Despite New Tempus AI Partnership - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 47 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 12.4 (%) |
| Held by Institutions | 67.2 (%) |
| Shares Short | 978 (K) |
| Shares Short P.Month | 208 (K) |
| EPS | -0.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.33 |
| Profit Margin | -108.6 % |
| Operating Margin | -754.1 % |
| Return on Assets (ttm) | -53.7 % |
| Return on Equity (ttm) | -13.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.56 |
| Sales Per Share | 0.3 |
| EBITDA (p.s.) | -2.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -95 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -3.63 |
| PEG Ratio | 0 |
| Price to Book value | 0.69 |
| Price to Sales | 7.6 |
| Price to Cash Flow | -1.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|